头颈部鳞癌相关生物标志物与免疫治疗预后的关系

doi:10.11904/j.issn.1002-3070.2021.01.011

Abstract

Abstract: Head and neck squamous cell carcinoma(HNSCC)is the sixth most common malignant tumor in the world,with an annual incidence of more than 550,000 cases and 300,000 deaths.Smoking and drinking alcohol are the main risk factors.The treatment plan of HNSCC is mainly based on TNM staging and primary surgery with comprehensive therapy(radiotherapy,chemotherapy and biological therapy).For the treatment of HNSCC,the 5-year survival rate has not improved in recent years.Therefore,new treatment methods are needed to increase the survival rate and improve the quality of patient life.The current research hotspot is the widespread application of immunotherapy-based biological targeted therapy for HNSCC.This study aims to explore the relationship between biomarkers of HNSCC and prognosis of immunotherapy.

Key words: Head and neck squamous cell carcinoma(HNSCC), HPV, p16, EBV, Prognosis, Immunotherapy

CLC Number:

R739.81

ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy[J]. Journal of Practical Oncology, 2021, 35(1): 55-58.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/55

References

1 Castellsagué X,Alemany L,Quer M,et al.HPV involvement in head and neck cancers:comprehensive assessment of biomarkers in 3680 patients[J].J Natl Cancer Inst,2016,108(6):403.
2 Fung N,Faraji F,Kang H,et al.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma[J].Cancer Metastasis Reviews,2017,36(3):449-461.
3 Ang KK,Harris J,Wheeler R,et al.Human papillomavirus and survival of patients with oropharyngeal cancer[J].N Engl J Med,2010,363(1):24-35.
4 Partlová S,Bouˇc ek J,Kloudová K,et al.Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma[J].Oncoimmunology,2015,4(1):e965570.
5 Wherry EJ,Ha SJ,Kaech SM,et al.Molecular signature of CD8⁺T cell exhaustion during chronic viral infection[J].Immunity,2007,27(4):670-684.
6 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet Oncol,2016,17(7):956-965.
7 Seiwert TY,Zuo Z,Keck MK,et al.Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas[J].Clin Cancer Res,2015,21(3):632-641.
8 Nasri E,Wiesen LB,Knapik JA,et al.Eps8 expression is significantly lower in p16+ head and neck squamous cell carcinomas(HNSCCs)compared with p16-HNSCCs[J].Hum Pathol,2018,72:45-51.
9 Ferris RL,Blumenschein G Jr,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].N Engl J Med,2016,375(19):1856-1867.
10 Prigge ES,Arbyn M,von Knebel Doeberitz M,et al.Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas:a systematic review and meta-analysis[J].Int J Cancer,2017,140(5):1186-1198.
11 Cai L,Ye Y,Jiang Q,et al.Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma[J].Nat Commun,2015,6:7353.
12 Kang H,Kiess A,Chung CH.Emerging biomarkers in head and neck cancer in the era of genomics[J].Nat Rev Clin Oncol,2015,12(1):11-26.
13 Chan JY,Wong ST.The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma[J].Laryngoscope,2014,124(1):126-130.
14 Straathof KC,Bollard CM,Popat U,et al.Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes[J].Blood,2005,105(5):1898-1904.
15 Louis CU,Straathof K,Bollard CM,et al.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma[J].J Immunother,2010,33(9):983-990.
16 Comoli P,Pedrazzoli P,Maccario R,et al.Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes[J].J Clin Oncol,2005,23(35):8942-8949.
17 Li YY,Chung GT,Lui VW,et al.Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations[J].Nat commun,2017,8:14121.
18 张锐,王智煜,文孝婷,等.肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J].实用肿瘤学杂志,2016,30(2):167-171.
19 Cristescu R,Mogg R,Ayers M,et al.Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J].Science,2018,362(6411):3593.
20 Solomon B,Young RJ,Rischin D.Head and neck squamous cell carcinoma:genomics and emerging biomarkers for immunomodulatory cancer treatments[J].Semin Cancer Biol,2018,52(2):228-240.
21 Ferris RL.Immunology and immunotherapy of head and neck cancer[J].J Clin Oncol,2015,33(29):3293-3304.
22 Srivastava RM,Lee SC,Andrade Filho PA,et al.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients[J].Clin Cancer Res,2013,19(7):1858-1872.
23 Ohtani T,Yamada Y,Furuhashi A,et al.Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers[J].Int J Oncol,2014,45(5):2051-2057.
24 李川,李燕,白鹰.细胞因子疗法在肿瘤治疗中的应用[J].国际肿瘤学杂志,2013,40(8):590-592.

[1]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[2]	NIU Ming, YU Ge. Gankyrin promotes tumor proliferation,metastasis and cancer stem cell characteristic in breast cancer [J]. Journal of Practical Oncology, 2020, 34(6): 518-523.
[3]	ZUO Rui, JIN Lu, LIU Li, LIU Xiaojia, ZHAO Pengyu, XIANG Xiaoyan. Research progress of miR-409-3p and tumor [J]. Journal of Practical Oncology, 2020, 34(6): 554-559.
[4]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[5]	LIU Hengchang, WEI Ran, LI Chunxiang, LIU Zheng, CHEN Haipeng, GUAN Xu, ZHAO Zhixun, ZOU Shuangmei, WANG Xishan, JIANG Zheng. Expression of NOX4 in colon cancer and its relationship with prognosis [J]. Journal of Practical Oncology, 2020, 34(5): 391-397.
[6]	SUN Xiaoyan, ZHANG Xiaoyan. Prognostic significance of lncRNA-SChLAP1 high-expression in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 425-429.
[7]	YIN Songxiang. Expression of Copine-8 in gastric cancer and its correlations with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(5): 430-435.
[8]	WEI Yong, ZHANG Yuhai, LV Shuangshuang, LI Yuemin. Effect of myasthenia gravis on prognosis of thymoma patients [J]. Journal of Practical Oncology, 2020, 34(4): 341-346.
[9]	XIE Xianxin,WEI Jun,QIU Jiaxin,WANG Cong,JIANG Daqing. Analysis of histopathological information and prognosis of residual tumor in neoadjuvant chemotherapy for breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 225-231.
[10]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[11]	WANG Zhao,FENG Yue,XING Linan,ZHANG Yunyan. Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy [J]. Journal of Practical Oncology, 2020, 34(3): 271-275.
[12]	CAO Ning,XIA Bairong,LOU Ge. Research progress of HPV proteins,miRNAs and exosomes in the inflammation of cervical cancer [J]. Journal of Practical Oncology, 2020, 34(3): 282-285.
[13]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.
[14]	SU Wenjia, WANG Shuye. Prognostic stratification and treatment progress of follicular lymphoma [J]. Journal of Practical Oncology, 2020, 34(2): 189-192.
[15]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.

The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments